XML 29 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Cash flows from operating activities:    
Net income $ 5,720 $ 4,006
Depreciation and amortization 1,636 1,299
Stock based compensation 349 287
Change in assets and liabilities, net of acquisitions    
Accounts receivable, net 914 652
Inventories 857 (406)
Prepaid expenses 134 331
Accounts payable (119) (230)
Accrued liabilities (582) 1,092
Net cash flows from operating activities 8,909 7,031
Cash flows from investing activities:    
Business acquisitions and intangibles (712) (17,973)
Capital expenditures, building   (2,150)
Capital expenditures (545) (428)
Net cash used in investing activities (1,257) (20,551)
Cash flows from financing activities:    
Proceeds from debt   7,000
Payments on debt (4,750) (778)
Dividends paid (1,216) (1,097)
Treasury stock purchases (60) (84)
Proceeds from stock options exercised 519 137
Net cash (used in) provided by financing activities (5,507) 5,178
Net increase (decrease) in cash and cash equivalents 2,145 (8,342)
Cash and cash equivalents at beginning of period 3,546 10,471
Cash and cash equivalents at end of period 5,691 2,129
Cash paid for:    
Income taxes 3,280 1,206
Interest 134 91
Supplemental disclosure of non-cash activity:    
Holdback amount from acquisition of the assets of Apex Laboratories 600  
Settlement of acquisition dues of Apex Laboratories, amount paid 562  
Settlement of acquisition dues of Apex Laboratories, return of accounts receivables 38  
The Company issued employee loans for the purchase of common stock during the nine month period ended December 31, 2011 and 2010, respectively 235 394
Loans outstanding retired $ 301